Citation: | LIU Dianlong, LI Jinglei, DI Mingyi, ZHANG Wei, HOU Wei. Clinical observation of Xiaoaiping Injection combined with TP regimen in the treatment of advanced non-small cell lung cancer with phlegm-damp-stasis syndrome[J]. Chinese Journal of General Practice, 2023, 21(3): 389-392. doi: 10.16766/j.cnki.issn.1674-4152.002890 |
[1] |
赵论, 张浩然, 石默晗, 等. 安罗替尼联合多西他赛二线治疗无驱动基因晚期非小细胞肺癌的临床疗效观察[J]. 中华全科医学, 2020, 18(4): 537-541. doi: 10.16766/j.cnki.issn.1674-4152.001292
ZHAO L, ZHANG H R, SHI M H, et al. Clinical observation of second-line treatment of anlotinib combined with docetaxel on advanced non-small cell lung cancer without driver gene mutation[J]. Chinese Journal of General Practice, 2020, 18(4): 537-541. doi: 10.16766/j.cnki.issn.1674-4152.001292
|
[2] |
于欣欣. 多西他赛单药治疗老年晚期非小细胞肺癌的应用效果研究[J]. 中国现代药物应用, 2020, 14(13): 186-187. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWYY202013086.htm
YU X X. To study the effect of docetaxel monotherapy in the treatment of elderly patients with advanced non-small cell lung cancer[J]. Chinese Journal of Modern Drug Application, 2020, 14(13): 186-187. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWYY202013086.htm
|
[3] |
李琳琳, 项保利, 薛乾隆, 等. 吉西他滨对非小细胞肺癌患者化疗疗效与其病理组织基因表达的相关性[J]. 中国临床药理学杂志, 2018, 34(7): 793-795, 799. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201807017.htm
LI L L, XIANG B L, XUE Q L, et al. Chemotherapeutic effect of gemcitabine for non-small cell lung cancer patients and the correlation with the expression of gene in pathological tissue[J]. The Chinese Journal of Clinical Pharmacology, 2018, 34(7): 793-795, 799. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201807017.htm
|
[4] |
徐家亮, 徐春华, 姜美慧, 等. 精确放疗联合吉非替尼治疗老年EGFR突变阳性局部晚期非小细胞肺癌的疗效[J]. 中国现代药物应用, 2020, 14(20): 117-119. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWYY202020055.htm
XU J L, XU C H, JIANG M H, et al. Efficacy of precision radiotherapy combined with gefitinib in the treatment of elderly patients with EGFR mutation-positive locally advanced non-small cell lung cancer[J]. Chinese Journal of Modern Drug Application, 2020, 14(20): 117-119. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWYY202020055.htm
|
[5] |
李琳琳, 项保利, 薛乾隆. 西罗莫司对肺癌细胞增殖及哺乳动物西罗莫司靶蛋白信号通路相关蛋白表达的影响[J]. 中国临床药理学杂志, 2018, 34(14): 1645-1648. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201814017.htm
LI L L, XIANG B L, XUE Q L, et al. Effect of rapamycin on the proliferation of lung carcinoma cell and the expression of mammalian target of rapamycin signal path related protein[J]. The Chinese Journal of Clinical Pharmacology, 2018, 34(14): 1645-1648. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201814017.htm
|
[6] |
陆小芳, 周晓荣, 钱东林, 等. 吉西他滨注射液联合顺铂注射液治疗中晚期非小细胞肺癌患者的临床研究[J]. 中国临床药理学杂志, 2021, 37(7): 805-808. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ202107004.htm
LU X F, ZHOU X R, QIAN D L, et al. Clinical trial of gemcitabine injection combined with cisplatin injection in the treatment of patients with advanced non-small cell lung cancer[J]. The Chinese Journal of Clinical Pharmacology, 2021, 37(7): 805-808. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ202107004.htm
|
[7] |
National Institutes of Health (NIH).Cancer stat facts: lung and bronchus cancer[EB/OL].[2019-06-02].
|
[8] |
张坦, 王艺曈, 方翼. 非小细胞肺癌靶向治疗药物的研究现状[J]. 中国临床药理学杂志, 2017, 33(11): 1054-1057. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201711029.htm
ZHANG T, WANG Y T, FANG Y. Research status of targeted agents for the treatment of non-small cell lung cancer[J]. The Chinese Journal of Clinical Pharmacology, 2017, 33(11): 1054-1057. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201711029.htm
|
[9] |
何碧珊. 中国老年晚期非小细胞肺癌患者使用奥希替尼不良反应分析[J]. 临床合理用药杂志, 2020, 13(19): 12-15. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY202019005.htm
HE B S. Analysis of adverse reactions of osimertinib among elderly patients with advanced non-small cell lung cancer in China[J]. Chinese Journal of Clinical Rational Drug Use, 2020, 13(19): 12-15. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY202019005.htm
|
[10] |
康乐, 苗晋鑫, 方晓艳, 等. 基于网络药理学及分子对接的通关藤治疗非小细胞肺癌的现代机制[J]. 重庆理工大学学报(自然科学), 2021, 35(7): 191-200. https://www.cnki.com.cn/Article/CJFDTOTAL-CGGL202107024.htm
KANG L, MIAO J X, FANG X Y, et al. Modern mechanism of marsdenia tenacissima in the treatment of non-small cell lung cancer based on network pharmacology and molecular docking[J]. Journal of Chongqing University of Technology: Natural Science, 2021, 35(7): 191-200. https://www.cnki.com.cn/Article/CJFDTOTAL-CGGL202107024.htm
|
[11] |
张梦迪, 牟睿宇, 刘宏根, 等. 消癌平注射液联合化疗治疗晚期非小细胞肺癌的Meta分析[J]. 天津中医药, 2019, 36(5): 466-473. https://www.cnki.com.cn/Article/CJFDTOTAL-TJZY201905014.htm
ZHANG M D, MOU R Y, LIU H G, et al. Meta-analysis of Xiaoaiping Injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer[J]. Tianjin Journal of Traditional Chinese Medicine, 2019, 36(5): 466-473. https://www.cnki.com.cn/Article/CJFDTOTAL-TJZY201905014.htm
|
[12] |
胡晓琳, 刘喜松, 陈细定. 消癌平注射液联合吉西他滨和卡铂治疗ⅢB和Ⅳ期非小细胞肺癌的临床评价[J]. 药物评价研究, 2017, 40(2): 266-269. https://www.cnki.com.cn/Article/CJFDTOTAL-YWPJ201702027.htm
HU X L, LIU X S, CHEN X D. Clinical effect of Xiaoaiping Injection combined with gemcitabine and carboplatin in treatment of ⅢB and Ⅳ non-small cell lung cancer[J]. Drug Evaluation Research, 2017, 40(2): 266-269. https://www.cnki.com.cn/Article/CJFDTOTAL-YWPJ201702027.htm
|
[13] |
姜婷婷, 张梦培, 王志恒, 等. 基于现代文献比较分析老年晚期非小细胞肺癌临床试验疗效终点指标[J]. 世界中西医结合杂志, 2020, 15(5): 841-844, 849. https://www.cnki.com.cn/Article/CJFDTOTAL-SJZX202005014.htm
JIANG T T, ZHANG M P, WANG Z H, et al. Comparative analysis of efficacy endpoints in clinical trials of elderly patients with advanced non-small cell lung cancer[J]. World Journal of Integrated Traditional and Western Medicine, 2020, 15(5): 841-844, 849. https://www.cnki.com.cn/Article/CJFDTOTAL-SJZX202005014.htm
|
[14] |
林洪生. 恶性肿瘤中医诊疗指南[M]. 北京: 人民卫生出版社, 2014: 242-267.
LIN H S. Guidelines for traditional Chinese medicine diagnosis and treatment of malignant tumors[M]. Beijing: People's Medical Press, 2014: 242-267.
|
[15] |
MAZIERES J, KOWALSKI D, LUFT A, et al. Health-related quality of life with carboplatin-paclitaxel or nab-paclitaxel with or without pembrolizumab in patients with metastatic squamous non-small-cell lung cancer[J]. J Clin Oncol, 2020, 38(3): 271-280.
|
[16] |
WANG P L, YANG J, ZHU Z F, et al. Marsdenia tenacissima: a review of traditional uses, phytochemistry and pharmacology[J]. Am J Chin Med, 2018. DOI: 10.1142/S0192415X18500751.
|
[17] |
CHEN J J, ZHANG X Q, XIAO X, et al. Xiao-Ai-Ping injection enhances effect of paclitaxel to suppress breast cancer proliferation and metastasis via activating transcription factor 3[J]. Integr Cancer Ther, 2020, 19: 1534735420906463. DOI: 10.1177/1534735420906463.
|
[18] |
朱丽娜, 武文辉, 钟敏, 等. 消癌平联合吉非替尼对进展期非小细胞肺癌患者凝血功能及临床疗效的影响[J]. 实用癌症杂志, 2020, 35(1): 77-81. https://www.cnki.com.cn/Article/CJFDTOTAL-SYAZ202001021.htm
ZHU L N, WU W H, ZHONG M, et al. Clinical effect of XiaoAiPing Injection combined with gefitinib on blood coagulation state of advanced NSCLC patients[J]. The Practical Journal of Cancer, 2020, 35(1): 77-81. https://www.cnki.com.cn/Article/CJFDTOTAL-SYAZ202001021.htm
|
[19] |
段桦, 胡凯文, 崔慧娟, 等. 108例老年晚期非小细胞肺癌患者预后因素分析[J]. 癌症进展, 2020, 18(5): 470-474. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ202005011.htm
DUAN H, HU K W, CUI H J, et al. Multivariate analysis of prognostic factors in the elderly patients with advanced non-small cell lung cancer: a study of 108 patients[J]. Oncology Progress, 2020, 18(5): 470-474. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ202005011.htm
|
[20] |
张添威, 陈卫建, 张蓉映, 等. 基于"痰毒"理论探讨化痰解毒法对中晚期非小细胞肺癌患者带瘤生存的临床意义[J]. 中华全科医学, 2019, 17(12): 2042-2045, 2150. doi: 10.16766/j.cnki.issn.1674-4152.001123
ZHANG T W, CHEN W J, ZHANG R Y, et al. Clinical significance of phlegm detoxification on survival with tumor in advanced NSCLC patients based on the phlegm-poison theory[J]. Chinese Journal of General Practice, 2019, 17(12): 2042-2045, 2150. doi: 10.16766/j.cnki.issn.1674-4152.001123
|
[21] |
苏连华. 祛瘀泻肺汤治疗痰湿壅肺兼血瘀型COPD急性加重期临床疗效[J]. 中国误诊学杂志, 2021, 16(2): 111-113. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWZX202102006.htm
SU L H. Analysis of clinical effect of Quyu Xiefei Decoction on acute exacerbation on COPD with phlegm-dampness obstructing lung and blood stasis[J]. Chinese Journal of Misdiagnostics, 2021, 16(2): 111-113. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWZX202102006.htm
|
[22] |
DAL BELLO M G, FILIBERTI R A, ALAMA A, et al. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients[J]. J Transl Med, 2019, 17(1): 74.
|
[23] |
胡彦辉, 崔庆丽, 马东阳, 等. 消癌平注射液对非小细胞肺癌患者T淋巴细胞亚群的影响[J]. 中国临床医生杂志, 2019, 47(5): 570-573. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLYS201905025.htm
HU Y H, CUI Q L, MA D Y, et al. Effect of Xiaoaiping injection on T lymphocyte subsets in patients with non-small cell lung cancer[J]. Chinese Journal for Clinicians, 2019, 47(5): 570-573. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLYS201905025.htm
|
[24] |
王祁民, 孙利民, 许剑峰. 通关藤及其制剂消癌平抗肿瘤的相关性研究[J]. 临床误诊误治, 2017, 30(12): 102-105. https://www.cnki.com.cn/Article/CJFDTOTAL-LCWZ201712039.htm
WANG Q M, SUN L M, XU J F. Correlation study of MTE and its preparation Xiaoaiping against tumor[J]. Clinical Misdiagnosis & Mistherapy, 2017, 30(12): 102-105. https://www.cnki.com.cn/Article/CJFDTOTAL-LCWZ201712039.htm
|